https://www.live-feeds.com/feed/abbvie-sharpens-immunology-focus-with-10-9-billion-apogee-dealContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/abbvie-sharpens-immunology-focus-with-10-9-billion-apogee-dealhttps://www.live-feeds.com/feed/abbvie-sharpens-immunology-focus-with-10-9-billion-apogee-deal#u14352Fri, 26 Jun 2026 12:47:23 +0000AbbVie is buying Waltham-based Apogee Therapeutics to expand its immunology and inflammatory disease pipeline. This $10.9 billion deal is the company's largest buyout in over five years. The acquisition provides AbbVie with a late-phase eczema drug candidate.What's confirmed:AbbVie is buying Apogee Therapeutics for $10.9 billion.The deal is the largest buyout for AbbVie in more than five years.Apogee Therapeutics is a biotech company based in Waltham.The acquisition targets long-acting autoimmune drugs and treatments for inflammatory diseases.Still unconfirmed:The deal includes the lead d